R

R&G PharmaStudies Co Ltd
SZSE:301333

Watchlist Manager
R&G PharmaStudies Co Ltd
SZSE:301333
Watchlist
Price: 51.88 CNY 1.63%
Market Cap: 5B CNY
Have any thoughts about
R&G PharmaStudies Co Ltd?
Write Note

R&G PharmaStudies Co Ltd
Income to Minority Interest

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

R&G PharmaStudies Co Ltd
Income to Minority Interest Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income to Minority Interest CAGR 3Y CAGR 5Y CAGR 10Y
R
R&G PharmaStudies Co Ltd
SZSE:301333
Income to Minority Interest
-ÂĄ328.4k
CAGR 3-Years
39%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Income to Minority Interest
-ÂĄ89.9m
CAGR 3-Years
-39%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Income to Minority Interest
ÂĄ67.4m
CAGR 3-Years
20%
CAGR 5-Years
43%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Income to Minority Interest
-ÂĄ380.9m
CAGR 3-Years
-97%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Income to Minority Interest
-ÂĄ66.5m
CAGR 3-Years
52%
CAGR 5-Years
-2%
CAGR 10-Years
-27%
W
WuXi XDC Cayman Inc
HKEX:2268
Income to Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

R&G PharmaStudies Co Ltd
Glance View

Market Cap
5B CNY
Industry
Life Sciences Tools & Services

R&G PharmaStudies Co., Ltd. engages in the provision of clinical trial outsourcing services. The company is headquartered in Beijing, Beijing and currently employs 1,926 full-time employees. The company went IPO on 2022-08-02. The firm's main businesses include clinical trial operation services (CO Services), clinical trial site management services (SMO Services), biological sample testing services (BA Services), data management and statistical analysis services (DM/ST Services), clinical trials Consulting Services, Clinical Pharmacology Services (CP Services) and others. The firm operates its businesses primarily in the domestic market.

Intrinsic Value
59.36 CNY
Undervaluation 13%
Intrinsic Value
Price
R

See Also

What is R&G PharmaStudies Co Ltd's Income to Minority Interest?
Income to Minority Interest
-328.4k CNY

Based on the financial report for Dec 31, 2023, R&G PharmaStudies Co Ltd's Income to Minority Interest amounts to -328.4k CNY.

What is R&G PharmaStudies Co Ltd's Income to Minority Interest growth rate?
Income to Minority Interest CAGR 3Y
39%

Over the last year, the Income to Minority Interest growth was 52%. The average annual Income to Minority Interest growth rates for R&G PharmaStudies Co Ltd have been 39% over the past three years .

Back to Top